Sirolimus and secondary skin-cancer prevention in kidney transplantation.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  New England Journal of Medicine

• Publication date

  2012-07-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJMoa1204166PMID 22830463
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Randomized Controlled Trial of Sirolimus for Renal Transplant Recipients at High Risk for Nonmelanoma Skin Cancer

  2012cited by this paper
• Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.

  2011cited by this paper
• Lower Malignancy Rates in Renal Allograft Recipients Converted to Sirolimus-Based, Calcineurin Inhibitor-Free Immunotherapy: 24-Month Results From the CONVERT Trial

  2011cited by this paper
• A Case–Control Study of Betapapillomavirus Infection and Cutaneous Squamous Cell Carcinoma in Organ Transplant Recipients

  2011cited by this paper
• The Changing Role of mTOR Kinase in the Maintenance of Protein Synthesis during Human Cytomegalovirus Infection

  2011cited by this paper
• Cytomegalovirus Incidence Between Everolimus Versus Mycophenolate in De Novo Renal Transplants: Pooled Analysis of Three Clinical Trials

  2011cited by this paper
• Rapamycin Blocks Production of KSHV/HHV8: Insights into the Anti-Tumor Activity of an Immunosuppressant Drug

  2011cited by this paper
• Switch to a Sirolimus‐Based Immunosuppression in Long‐Term Renal Transplant Recipients: Reduced Rate of (Pre‐)Malignancies and Nonmelanoma Skin Cancer in a Prospective, Randomized, Assessor‐Blinded, Controlled Clinical Trial

  2010cited by this paper
• Early and late effects of the immunosuppressants rapamycin and mycophenolate mofetil on UV carcinogenesis

  2010cited by this paper
• Rapamycin-Resistant mTORC1 Kinase Activity Is Required for Herpesvirus Replication

  2010cited by this paper
• Subsequent Squamous- and Basal-Cell Carcinomas in Kidney-Transplant Recipients After the First Skin Cancer: Cumulative Incidence and Risk Factors

  2010cited by this paper
• Calcineurin and ATF3: opposite roles in squamous skin cancer

  2010cited by this paper
• Organ transplantation and skin cancer: basic problems and new perspectives

  2010cited by this paper
• Sirolimus and kidney growth in autosomal dominant polycystic kidney disease.

  2010cited by this paper
• The Human Papillomavirus Type 16 E6 Oncoprotein Activates mTORC1 Signaling and Increases Protein Synthesis

  2010cited by this paper
• Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

  2009cited by this paper
• Conversion From Calcineurin Inhibitors to Sirolimus Maintenance Therapy in Renal Allograft Recipients: 24-Month Efficacy and Safety Results From the CONVERT Trial

  2009cited by this paper
• Conversion from calcineurin inhibitors to sirolimus reduces vascularization and thickness of post-transplant cutaneous squamous cell carcinomas.

  2009cited by this paper
• Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.

  2008cited by this paper
• Skin Cancer in Organ Transplant Recipients—Where Do We Stand Today?

  2008cited by this paper
• Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.

  2008cited by this paper
• mTOR, Cancer and Transplantation

  2008cited by this paper
• Clinically Relevant Immunosuppressants Influence UVB‐Induced Tumor Size Through Effects on Inflammation and Angiogenesis

  2007cited by this paper
• Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

  2007cited by this paper
• Subsequent Skin Cancers in Kidney and Heart Transplant Recipients after the First Squamous Cell Carcinoma

  2006cited by this paper
• Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation.

  2006cited by this paper
• Influence of Co‐Medication with Sirolimus or Cyclosporine on Mycophenolic Acid Pharmacokinetics in Kidney Transplantation

  2005cited by this paper
• Maintenance Immunosuppression with Target-of-Rapamycin Inhibitors is Associated with a Reduced Incidence of De Novo Malignancies

  2005cited by this paper
• Immunosuppressive drugs and the risk of cancer after organ transplantation.

  2005cited by this paper
• Reduction of Immunosuppression for Transplant‐Associated Skin Cancer: Rationale and Evidence of Efficacy

  2005cited by this paper
• PRO- AND ANTI-CANCER EFFECTS OF IMMUNOSUPPRESSIVE AGENTS USED IN ORGAN TRANSPLANTATION

  2004cited by this paper
• Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal.

  2004cited by this paper
• RAPAMYCIN PROTECTS ALLOGRAFTS FROM REJECTION WHILE SIMULTANEOUSLY ATTACKING TUMORS IN IMMUNOSUPPRESSED MICE

  2004cited by this paper
• Two‐year incidence of malignancy in sirolimus‐treated renal transplant recipients: results from five multicenter studies *

  2004cited by this paper
• Tacrolimus enhances transforming growth factor-&bgr;1 expression and promotes tumor progression

  2003cited by this paper
• Skin cancers after organ transplantation.

  2003cited by this paper
• Skin cancers after organ transplantation.

  2003cited by this paper
• Cyclosporine induces cancer progression by a cell-autonomous mechanism

  1999cited by this paper
• Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens.

  1998cited by this paper
• A non-parametric test for interval-censored failure time data with application to AIDS studies.

  1996cited by this paper
• IgG-Subklassen der menschlichen Immunglobuline

  1976cited by this paper

• Cumulative exposure to tacrolimus is associated with increased risk of malignancy for solid organ transplant recipients.

  2026cites this paper
• Outcomes of microvascular head and neck reconstruction in solid organ transplant patients: a single institution experience and meta-analysis

  2026cites this paper
• Sirolimus for Secondary Prevention of Cutaneous Squamous Cell Carcinoma in Kidney Transplant Recipients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

  2026cites this paper
• Theragnostic approach of venous malformations in 2025: similarities and differences with oncology advances.

  2025cites this paper
• Redefining Immunosuppression in Older Kidney Transplant Recipients: Reflections on the OPTIMIZE Study.

  2025cites this paper
• Algorithmes de prise en charge thérapeutique du carcinome épidermoïde cutané invasif. Recommandations de prise en charge du Groupe de Cancérologie Cutanée de la Société Française de Dermatologie

  2025cites this paper
• Skin Cancer in Transplant Recipients: time to revisit immunosuppression trials?

  2025cites this paper
• Evaluation of the potential application of RAPA-based delivery: Structural evolution and biocompatibility of monodispersed nano-ZIF-8@RAPA

  2025cites this paper
• Immunosuppressant Drug Specific Risk of Malignancy After Organ Transplantation: A Population-Based Analysis of Texas Medicare Beneficiaries

  2025cites this paper
• Chemoprevention of Keratinocyte Cancers: Could Aspirin Be the Solution?

  2025cites this paper
• Targeting mTOR Kinase for Cancer Treatment: A Comprehensive Review With Clinical Insights

  2025cites this paper
• Consensus-based Recommendations on the Management of Immunosuppression After Squamous Cell Carcinoma Diagnosis in Kidney Transplant Recipients: An International Delphi Consensus Statement

  2025cites this paper
• Immunosuppressants/Immunomodulators and Malignancy

  2025cites this paper
• The underestimated skin cancer risk after liver transplantation: a systematic review and meta-analysis.

  2025cites this paper
• Cutaneous Squamous Cell Carcinoma in Immunocompromised Patients

  2025cites this paper
• Management of Cutaneous Squamous Cell Carcinoma: A Literature Review and Update.

  2025cites this paper
• Nicotinamide for Skin Cancer Chemoprevention.

  2025cites this paper
• Epidemiology and Risk Factors of Actinic Keratosis. What is New for The Management for Sun-Damaged Skin

  2024cites this paper
• Topical sirolimus in dermatology: a systematic review.

  2024cites this paper
• Current Advances and Challenges in the Management of Cutaneous Squamous Cell Carcinoma in Immunosuppressed Patients

  2024cites this paper
• Skin cancer in renal transplant recipients: outcomes from a safety net hospital in Boston

  2024influential citation
• Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma

  2024cites this paper
• Predicting Tacrolimus Concentrations in the Skin of Adult Kidney Transplant Recipients: A Feasibility Study

  2024cites this paper
• Cutaneous squamous cell carcinoma in solid organ transplant recipients: Current therapeutic and screening strategies.

  2024cites this paper
• Cancer Screening and Cancer Treatment in Kidney Transplant Recipients

  2024cites this paper
• Top 50 Most Cited Articles in Transplant Dermatology: A Bibliometric Analysis

  2024cites this paper
• Cutaneous Squamous Cell Carcinoma: An Updated Review

  2024cites this paper
• Post-Kidney Transplant Cancer: A Real-World Retrospective Analysis From a Single Italian Center

  2024cites this paper
• Primary prophylaxis with mTOR inhibitor enhances T cell effector function and prevents heart transplant rejection during talimogene laherparepvec therapy of squamous cell carcinoma

  2024influential citation
• Calcineurin‐Inhibitor Discontinuation Could Reduce the Risk of De Novo Malignancies After Liver Transplantation for Alcohol‐Related Liver Disease

  2024cites this paper
• Trial protocol for SiroSkin: a randomised double-blind placebo-controlled trial of topical sirolimus in chemoprevention of facial squamous cell carcinomas in solid organ transplant recipients

  2024cites this paper
• Mammalian target of rapamycin inhibitors: A new‐possible approach for in‐utero medication therapy

  2024cites this paper
• Pediatric Kidney Transplantation: Cancer and Cancer Risk.

  2024cites this paper
• Skin cancer associated with calcineurin inhibitors treatment: analysis of FAERS database.

  2024cites this paper
• Treatment of skin cancers in solid organ transplant recipients: current status and future perspectives

  2024cites this paper
• Cutaneous Squamous Cell Carcinoma in Patients with Solid-Organ-Transplant-Associated Immunosuppression

  2024cites this paper
• Chemotherapy’s effects on autophagy in the treatment of Hodgkin’s lymphoma: a scoping review

  2024cites this paper
• Effectiveness and safety of immunosuppressive regimens used as maintenance therapy in kidney transplantation: The CESIT study

  2024cites this paper
• Immunotherapy for Advanced Skin Cancer in Kidney Transplant Recipients-The High-Risk Balancing Act.

  2024cites this paper
• Immunotherapy for Cancer in Kidney Transplant Patients: A Difficult Balance Between Risks and Benefits

  2024cites this paper
• Immunosuppresseurs en transplantation rénale : mécanismes d’action et suivi biologique

  2024cites this paper
• Immunity against Non-Melanoma Skin Cancer and the Effect of Immunosuppressive Medication on Non-Melanoma Skin Cancer Risk in Solid Organ Transplant Recipients

  2023cites this paper
• A review of heart transplant immunosuppressants and nonmelanoma skin cancer

  2023cites this paper
• Cutaneous squamous cell carcinoma of the eyelid in northern latitudes, a 25‐year experience in Finland

  2023cites this paper
• European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention-Update 2023.

  2023cites this paper
• Real-life use of mTOR inhibitor-based therapy in adults with autoimmune cytopenia highlights strong efficacy in relapsing/refractory multi-lineage autoimmune cytopenia

  2023cites this paper
• Use of sirolimus as an adjuvant therapy for kidney transplant recipients with high-risk cutaneous squamous cell carcinomas: a prospective non-randomized controlled study

  2023cites this paper
• Non-melanoma skin cancer outcomes in kidney transplant recipients converted from calcineurin inhibitors to mTOR inhibitors: a systematic review

  2023influential citation
• Uso do sirolimo como terapia adjuvante para receptores de transplante renal com carcinoma espinocelular cutâneo de alto risco: um estudo prospectivo controlado não randomizado

  2023cites this paper
• Advances in cutaneous squamous cell carcinoma

  2023cites this paper
• Prognostic Outcomes of Cutaneous Squamous Cell Carcinoma in Solid Organ Transplant Recipients: A Retrospective Comparative Cohort Study

  2023cites this paper
• Immune Checkpoint Inhibitors in Solid Organ Transplant Recipients With Advanced Skin Cancers—Emerging Strategies for Clinical Management

  2023cites this paper
• Cancer prevention with rapamycin

  2023cites this paper
• Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients.

  2023cites this paper
• Immunomodulators for Non-Melanoma Skin Cancers: Updated Perspectives

  2023cites this paper
• A nanotherapeutic strategy that engages cytotoxic and immunosuppressive activities for the treatment of cancer recurrence following organ transplantation

  2023cites this paper
• Multicenter analysis of immunosuppressive medications on the risk of malignancy following adult solid organ transplantation

  2023cites this paper
• Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022

  2023cites this paper
• Local blockade of tacrolimus promotes T-cell-mediated tumor regression in systemically immunosuppressed hosts

  2023cites this paper
• Use of immune checkpoint inhibitors in solid organ transplant recipients with advanced cutaneous malignancies

  2023cites this paper
• Epidemiology and risk factors for multiple squamous cell carcinomas in a cohort of organ transplant recipients from northern Italy: a single center study.

  2023cites this paper
• German S3 guideline “actinic keratosis and cutaneous squamous cell carcinoma” – long version of the update 2023

  2023cites this paper
• Immune checkpoint blockade for organ-transplant recipients with cancer: A review.

  2022cites this paper
• Risk of skin cancer in kidney, liver and heart recipients: A nationwide population-based study in Taiwan.

  2022cites this paper
• Differences in Skin Cancer Rates by Transplanted Organ Type and Patient Age After Organ Transplant in White Patients.

  2022cites this paper
• Melanoma risk during immunomodulating treatment

  2022cites this paper
• Therapeutic Antiaging Strategies

  2022cites this paper
• Characterization and management of facial angiofibroma related to tuberous sclerosis complex in the United States: retrospective analysis of the natural history database

  2022cites this paper
• Managing immune checkpoint inhibition in transplant recipients.

  2022cites this paper
• Medical Aspects of mTOR Inhibition in Kidney Transplantation

  2022cites this paper
• Transplant Onconephrology in Patients With Kidney Transplants.

  2022cites this paper
• Characteristics, outcomes, and predictors of de novo malignancy after heart transplantation

  2022cites this paper
• New immunosuppressive agents in transplantation.

  2022cites this paper
• Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline - Update 2022.

  2022cites this paper
• Response to "Comments on sirolimus use and risk of cutaneous squamous cell carcinoma (SCC) in solid organ transplant recipients" (SOTRs).

  2022cites this paper
• Chemoprevention of cutaneous squamous cell carcinoma and its precursors in solid organ transplant recipients using topical sirolimus: a randomized, double-blind, placebo-controlled pilot trial.

  2022cites this paper
• Outcomes of Primary Mucosal Head and Neck Squamous Cell Carcinoma in Solid Organ Transplant Recipients

  2022cites this paper
• Topical treatment of actinic keratoses in organ transplant recipients: a feasibility study for SPOT (Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments)

  2022cites this paper
• Emerging Concepts in Managing Malignancy in Kidney Transplant Patients.

  2022cites this paper
• Mechanistic Target of Rapamycin (mTOR) Inhibitors.

  2022cites this paper
• Immune checkpoint inhibitors for solid organ transplant recipients: clinical updates

  2022cites this paper
• Acute Kidney Injury in Cancer Immunotherapy Recipients

  2022cites this paper
• Delivery of costimulatory blockade to lymph nodes promotes transplant acceptance in mice

  2022cites this paper
• Skin Cancer in Solid Organ Transplant Recipients: A Review for the Nondermatologist.

  2022cites this paper
• Scope and Consistency of Cancer Outcomes Reported in Randomized Trials in Kidney Transplant Recipients

  2022cites this paper
• Interventions After First Post-Transplant Cutaneous Squamous Cell Carcinoma: A Proposed Decision Framework

  2022cites this paper
• Mammalian target of rapamycin inhibitors for prolonged secondary prevention of nonmelanoma skin cancer in solid organ transplant recipients

  2022influential citation
• Acute Kidney Injury in a Patient With a Kidney Transplant and Posttransplant Lymphoproliferative Disorder: A Quiz.

  2022cites this paper
• Multicenter analysis of immunosuppressive medications on the subsequent risk of malignancy in solid organ transplant recipients

  2022cites this paper
• Skin cancer in immunosuppressed patients

  2022cites this paper
• Recent Advances in Immunotherapy for Patients with Head and Neck Cutaneous Squamous Cell Carcinoma

  2022cites this paper
• Post-transplant Lymphoproliferative Disorder Following Cardiac Transplantation

  2022cites this paper
• Transplant Onconephrology: An Update.

  2022cites this paper
• Spectrum of Nonkeratinocyte Skin Cancer Risk Among Solid Organ Transplant Recipients in the US.

  2022cites this paper
• Surgical Approach to Cutaneous Malignancy with Systemic Implications

  2021cites this paper
• The Puzzle of Immunosuppressive Drugs

  2021cites this paper
• Rôle des immunosuppresseurs dans le succès d’une greffe d’organe

  2021cites this paper
• Low-Dose Acitretin for Secondary Prevention of Keratinocyte Carcinomas in Solid-Organ Transplant Recipients

  2021cites this paper
• Recent Updates on the Involvement of PI3K/AKT/mTOR Molecular Cascade in the Pathogenesis of Hyperproliferative Skin Disorders

  2021cites this paper
• Skin Cancers and Lung Transplant

  2021cites this paper